ArticleEuropean journal of pediatrics2026
The frequency and characteristics of ultra-short celiac disease in children: A single-center experience.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDue to the patchy nature of mucosal involvement in Celiac disease (CD), histopathological changes may be confined to the duodenal bulb in some patients, leading to diagnostic challenges. This study aimed to investigate the frequency, as well as the clinical and serological characteristics, of ultra-short celiac disease (USCD) in children.
methodsBetween February 2024 and March 2026, pediatric patients diagnosed with CD based on separate biopsy specimens obtained from the duodenal bulb and distal duodenum, each placed in separate containers, were enrolled in this study. The patients were classified into two groups: the USCD group and the classic CD group.
resultsOf the 78 patients included, 47 (60.25%) were female, and the overall mean age at diagnosis was 9.58 ± 4.21 years. The median tissue transglutaminase IgA (tTG-IgA) level was 125.50 (IQR: 21.30-200.00) IU/L. Sixteen patients (20.51%) had histopathologically confirmed USCD. The median tTG-IgA level was significantly lower in the USCD group compared to the classic CD group (22.50 vs. 162.00 IU/L; p < 0.05). Additionally, 87.50% of the patients in the USCD group lacked the classic gastrointestinal symptoms typically associated with malabsorption, presenting instead with isolated growth retardation.
conclusionThe rate of isolated duodenal bulb involvement in children was remarkably high (20.51%). Ultra-short celiac disease is more prevalent in pediatric patients presenting with fewer classic gastrointestinal findings and tTG-IgA levels below 10 × ULN. Therefore, it is critically important to obtain at least one biopsy specimen from the duodenal bulb and place it in a separate container. Missing bulb biopsies may result in a significant proportion of patients with isolated duodenal bulb involvement going undiagnosed. What is known • The frequency of ultra-short celiac disease (USCD) varies between 2.4% and 22.0% for more accurate differentiation • Intestinal biopsy remains mandatory to diagnose CD in patients with tTG-IgA levels below 10 times the upper limit of normal (10 × ULN) • Duodenal bulb biopsies are not routinely performed even in specialized centers during endoscopy What is new • The frequency of USCD in children with CD was found to be relatively high (20.51%) • Among patients with USCD, 75.00% exhibited tTG-IgA levels below 10 × ULN • Systematic duodenal bulb biopsy substantially enhances USCD detection in patients with low tTG-IgA levels; without it, approximately one in five patients may remain undiagnosed.
Indexed as
Identifiers
42377610What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.